ITRACONAZOLE

Details

Stereochemistry	MIXED
Molecular Formula	C35H38Cl2N8O4
Molecular Weight	705.633
Optical Activity	( + / - )
Defined Stereocenters	2 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC(C)N1N=CN(C1=O)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(OC[C@H]5CO[C@@](CN6C=NC=N6)(O5)C7=C(Cl)C=C(Cl)C=C7)C=C4

InChI

InChIKey=VHVPQPYKVGDNFY-ZPGVKDDISA-N

InChI=1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C35H38Cl2N8O4
Molecular Weight	705.633
Charge	0
Count

Stereochemistry	EPIMERIC
Additional Stereochemistry	No
Defined Stereocenters	2 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020083s058,020657s033lbl.pdf

SPORANOX is the brand name for itraconazole, an azole antifungal agent. Itraconazole is a 1:1:1:1 racemic mixture of four diastereomers (two enantiomeric pairs), each possessing three chiral centers. In vitro studies have demonstrated that itraconazole inhibits the cytochrome P450-dependent synthesis of ergosterol, which is a vital component of fungal cell membranes. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Itraconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis. SPORANOX capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: Blastomycosis, pulmonary and extrapulmonary; Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, nonmeningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. SPORANOX is also indicated for the treatment of the following fungal infections in non-immunocompromised patients: Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Itraconazole is mainly metabolized through CYP3A4. Other drugs that either share this metabolic pathway or modify CYP3A4 activity may influence the pharmacokinetics of itraconazole. Similarly, itraconazole may modify the pharmacokinetics of other drugs that share this metabolic pathway. Itraconazole is a potent CYP3A4 inhibitor and a P-glycoprotein inhibitor. When using concomitant medication, it is recommended that the corresponding label be consulted for information on the route of metabolism and the possible need to adjust dosages.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cytochrome P450 51 28 Target ID: CHEMBL1780 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8257130	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Blastomycosis, pulmonary and extrapulmonary 2 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020083s058,020657s033lbl.pdf	Curative	Phase III 656	SPORANOX Approved Use SPORANOX® (itraconazole) Capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: Blastomycosis, pulmonary and extrapulmonary Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. SPORANOX® Capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. (See CLINICAL PHARMACOLOGY: Special Populations, CONTRAINDICATIONS, WARNINGS, and ADVERSE REACTIONS: Post-marketing Experience for more information.) Description of Clinical Studies Blastomycosis Analyses were conducted on data from two open-label, non-concurrently controlled studies (N=73 combined) in patients with normal or abnormal immune status. The median dose was 200 mg/day. A response for most signs and symptoms was observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 6 months. Results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of blastomycosis compared with the natural history of untreated cases. Histoplasmosis Analyses were conducted on data from two open-label, non-concurrently controlled studies (N=34 combined) in patients with normal or abnormal immune status (not including HIV-infected patients). The median dose was 200 mg/day. A response for most signs and symptoms was observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 12 months. Results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of histoplasmosis, compared with the natural history of untreated cases. Histoplasmosis in HIV-infected patients Data from a small number of HIV-infected patients suggested that the response rate of histoplasmosis in HIV-infected patients is similar to that of non-HIV-infected patients. The clinical course of histoplasmosis in HIV-infected patients is more severe and usually requires maintenance therapy to prevent relapse. Aspergillosis Analyses were conducted on data from an open-label, single-patient-use protocol designed to make itraconazole available in the U.S. for patients who either failed or were intolerant of amphotericin B therapy (N=190). The findings were corroborated by two smaller open-label studies (N=31 combined) in the same patient population. Most adult patients were treated with a daily dose of 200 to 400 mg, with a median duration of 3 months. Results of these studies demonstrated substantial evidence of effectiveness of itraconazole as a second-line therapy for the treatment of aspergillosis compared with the natural history of the disease in patients who either failed or were intolerant of amphotericin B therapy. Onychomycosis of the toenail Analyses were conducted on data from three double-blind, placebo-controlled studies (N=214 total; 110 given SPORANOX® Capsules) in which patients with onychomycosis of the toenails received 200 mg of SPORANOX® Capsules once daily for 12 consecutive weeks. Results of these studies demonstrated mycologic cure, defined as simultaneous occurrence of negative KOH plus negative culture, in 54% of patients. Thirty-five percent (35%) of patients were considered an overall success (mycologic cure plus clear or minimal nail involvement with significantly decreased signs) and 14% of patients demonstrated mycologic cure plus clinical cure (clearance of all signs, with or without residual nail deformity). The mean time to overall success was approximately 10 months. Twenty-one percent (21%) of the overall success group had a relapse (worsening of the global score or conversion of KOH or culture from negative to positive). Onychomycosis of the fingernail Analyses were conducted on data from a double-blind, placebo-controlled study (N=73 total; 37 given SPORANOX® Capsules) in which patients with onychomycosis of the fingernails received a 1-week course (pulse) of 200 mg of SPORANOX® Capsules b.i.d., followed by a 3-week period without SPORANOX®, which was followed by a second 1-week pulse of 200 mg of SPORANOX® Capsules b.i.d. Results demonstrated mycologic cure in 61% of patients. Fifty-six percent (56%) of patients were considered an overall success and 47% of patients demonstrated mycologic cure plus clinical cure. The mean time to overall success was approximately 5 months. None of the patients who achieved overall success relapsed. Launch Date 1992
Histoplasmosis 5 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020083s058,020657s033lbl.pdf	Curative	Approved 8429	SPORANOX Approved Use SPORANOX® (itraconazole) Capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: Blastomycosis, pulmonary and extrapulmonary Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. SPORANOX® Capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. (See CLINICAL PHARMACOLOGY: Special Populations, CONTRAINDICATIONS, WARNINGS, and ADVERSE REACTIONS: Post-marketing Experience for more information.) Description of Clinical Studies Blastomycosis Analyses were conducted on data from two open-label, non-concurrently controlled studies (N=73 combined) in patients with normal or abnormal immune status. The median dose was 200 mg/day. A response for most signs and symptoms was observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 6 months. Results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of blastomycosis compared with the natural history of untreated cases. Histoplasmosis Analyses were conducted on data from two open-label, non-concurrently controlled studies (N=34 combined) in patients with normal or abnormal immune status (not including HIV-infected patients). The median dose was 200 mg/day. A response for most signs and symptoms was observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 12 months. Results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of histoplasmosis, compared with the natural history of untreated cases. Histoplasmosis in HIV-infected patients Data from a small number of HIV-infected patients suggested that the response rate of histoplasmosis in HIV-infected patients is similar to that of non-HIV-infected patients. The clinical course of histoplasmosis in HIV-infected patients is more severe and usually requires maintenance therapy to prevent relapse. Aspergillosis Analyses were conducted on data from an open-label, single-patient-use protocol designed to make itraconazole available in the U.S. for patients who either failed or were intolerant of amphotericin B therapy (N=190). The findings were corroborated by two smaller open-label studies (N=31 combined) in the same patient population. Most adult patients were treated with a daily dose of 200 to 400 mg, with a median duration of 3 months. Results of these studies demonstrated substantial evidence of effectiveness of itraconazole as a second-line therapy for the treatment of aspergillosis compared with the natural history of the disease in patients who either failed or were intolerant of amphotericin B therapy. Onychomycosis of the toenail Analyses were conducted on data from three double-blind, placebo-controlled studies (N=214 total; 110 given SPORANOX® Capsules) in which patients with onychomycosis of the toenails received 200 mg of SPORANOX® Capsules once daily for 12 consecutive weeks. Results of these studies demonstrated mycologic cure, defined as simultaneous occurrence of negative KOH plus negative culture, in 54% of patients. Thirty-five percent (35%) of patients were considered an overall success (mycologic cure plus clear or minimal nail involvement with significantly decreased signs) and 14% of patients demonstrated mycologic cure plus clinical cure (clearance of all signs, with or without residual nail deformity). The mean time to overall success was approximately 10 months. Twenty-one percent (21%) of the overall success group had a relapse (worsening of the global score or conversion of KOH or culture from negative to positive). Onychomycosis of the fingernail Analyses were conducted on data from a double-blind, placebo-controlled study (N=73 total; 37 given SPORANOX® Capsules) in which patients with onychomycosis of the fingernails received a 1-week course (pulse) of 200 mg of SPORANOX® Capsules b.i.d., followed by a 3-week period without SPORANOX®, which was followed by a second 1-week pulse of 200 mg of SPORANOX® Capsules b.i.d. Results demonstrated mycologic cure in 61% of patients. Fifty-six percent (56%) of patients were considered an overall success and 47% of patients demonstrated mycologic cure plus clinical cure. The mean time to overall success was approximately 5 months. None of the patients who achieved overall success relapsed. Launch Date 1992
Aspergillosis, pulmonary and extrapulmonary 2 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020083s058,020657s033lbl.pdf	Curative	Approved 8429	SPORANOX Approved Use SPORANOX® (itraconazole) Capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: Blastomycosis, pulmonary and extrapulmonary Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. SPORANOX® Capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. (See CLINICAL PHARMACOLOGY: Special Populations, CONTRAINDICATIONS, WARNINGS, and ADVERSE REACTIONS: Post-marketing Experience for more information.) Description of Clinical Studies Blastomycosis Analyses were conducted on data from two open-label, non-concurrently controlled studies (N=73 combined) in patients with normal or abnormal immune status. The median dose was 200 mg/day. A response for most signs and symptoms was observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 6 months. Results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of blastomycosis compared with the natural history of untreated cases. Histoplasmosis Analyses were conducted on data from two open-label, non-concurrently controlled studies (N=34 combined) in patients with normal or abnormal immune status (not including HIV-infected patients). The median dose was 200 mg/day. A response for most signs and symptoms was observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 12 months. Results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of histoplasmosis, compared with the natural history of untreated cases. Histoplasmosis in HIV-infected patients Data from a small number of HIV-infected patients suggested that the response rate of histoplasmosis in HIV-infected patients is similar to that of non-HIV-infected patients. The clinical course of histoplasmosis in HIV-infected patients is more severe and usually requires maintenance therapy to prevent relapse. Aspergillosis Analyses were conducted on data from an open-label, single-patient-use protocol designed to make itraconazole available in the U.S. for patients who either failed or were intolerant of amphotericin B therapy (N=190). The findings were corroborated by two smaller open-label studies (N=31 combined) in the same patient population. Most adult patients were treated with a daily dose of 200 to 400 mg, with a median duration of 3 months. Results of these studies demonstrated substantial evidence of effectiveness of itraconazole as a second-line therapy for the treatment of aspergillosis compared with the natural history of the disease in patients who either failed or were intolerant of amphotericin B therapy. Onychomycosis of the toenail Analyses were conducted on data from three double-blind, placebo-controlled studies (N=214 total; 110 given SPORANOX® Capsules) in which patients with onychomycosis of the toenails received 200 mg of SPORANOX® Capsules once daily for 12 consecutive weeks. Results of these studies demonstrated mycologic cure, defined as simultaneous occurrence of negative KOH plus negative culture, in 54% of patients. Thirty-five percent (35%) of patients were considered an overall success (mycologic cure plus clear or minimal nail involvement with significantly decreased signs) and 14% of patients demonstrated mycologic cure plus clinical cure (clearance of all signs, with or without residual nail deformity). The mean time to overall success was approximately 10 months. Twenty-one percent (21%) of the overall success group had a relapse (worsening of the global score or conversion of KOH or culture from negative to positive). Onychomycosis of the fingernail Analyses were conducted on data from a double-blind, placebo-controlled study (N=73 total; 37 given SPORANOX® Capsules) in which patients with onychomycosis of the fingernails received a 1-week course (pulse) of 200 mg of SPORANOX® Capsules b.i.d., followed by a 3-week period without SPORANOX®, which was followed by a second 1-week pulse of 200 mg of SPORANOX® Capsules b.i.d. Results demonstrated mycologic cure in 61% of patients. Fifty-six percent (56%) of patients were considered an overall success and 47% of patients demonstrated mycologic cure plus clinical cure. The mean time to overall success was approximately 5 months. None of the patients who achieved overall success relapsed. Launch Date 1992
Onychomycosis 18 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020083s058,020657s033lbl.pdf	Curative	Approved 8429	SPORANOX Approved Use SPORANOX® (itraconazole) Capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: Blastomycosis, pulmonary and extrapulmonary Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. SPORANOX® Capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. (See CLINICAL PHARMACOLOGY: Special Populations, CONTRAINDICATIONS, WARNINGS, and ADVERSE REACTIONS: Post-marketing Experience for more information.) Description of Clinical Studies Blastomycosis Analyses were conducted on data from two open-label, non-concurrently controlled studies (N=73 combined) in patients with normal or abnormal immune status. The median dose was 200 mg/day. A response for most signs and symptoms was observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 6 months. Results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of blastomycosis compared with the natural history of untreated cases. Histoplasmosis Analyses were conducted on data from two open-label, non-concurrently controlled studies (N=34 combined) in patients with normal or abnormal immune status (not including HIV-infected patients). The median dose was 200 mg/day. A response for most signs and symptoms was observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 12 months. Results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of histoplasmosis, compared with the natural history of untreated cases. Histoplasmosis in HIV-infected patients Data from a small number of HIV-infected patients suggested that the response rate of histoplasmosis in HIV-infected patients is similar to that of non-HIV-infected patients. The clinical course of histoplasmosis in HIV-infected patients is more severe and usually requires maintenance therapy to prevent relapse. Aspergillosis Analyses were conducted on data from an open-label, single-patient-use protocol designed to make itraconazole available in the U.S. for patients who either failed or were intolerant of amphotericin B therapy (N=190). The findings were corroborated by two smaller open-label studies (N=31 combined) in the same patient population. Most adult patients were treated with a daily dose of 200 to 400 mg, with a median duration of 3 months. Results of these studies demonstrated substantial evidence of effectiveness of itraconazole as a second-line therapy for the treatment of aspergillosis compared with the natural history of the disease in patients who either failed or were intolerant of amphotericin B therapy. Onychomycosis of the toenail Analyses were conducted on data from three double-blind, placebo-controlled studies (N=214 total; 110 given SPORANOX® Capsules) in which patients with onychomycosis of the toenails received 200 mg of SPORANOX® Capsules once daily for 12 consecutive weeks. Results of these studies demonstrated mycologic cure, defined as simultaneous occurrence of negative KOH plus negative culture, in 54% of patients. Thirty-five percent (35%) of patients were considered an overall success (mycologic cure plus clear or minimal nail involvement with significantly decreased signs) and 14% of patients demonstrated mycologic cure plus clinical cure (clearance of all signs, with or without residual nail deformity). The mean time to overall success was approximately 10 months. Twenty-one percent (21%) of the overall success group had a relapse (worsening of the global score or conversion of KOH or culture from negative to positive). Onychomycosis of the fingernail Analyses were conducted on data from a double-blind, placebo-controlled study (N=73 total; 37 given SPORANOX® Capsules) in which patients with onychomycosis of the fingernails received a 1-week course (pulse) of 200 mg of SPORANOX® Capsules b.i.d., followed by a 3-week period without SPORANOX®, which was followed by a second 1-week pulse of 200 mg of SPORANOX® Capsules b.i.d. Results demonstrated mycologic cure in 61% of patients. Fifty-six percent (56%) of patients were considered an overall success and 47% of patients demonstrated mycologic cure plus clinical cure. The mean time to overall success was approximately 5 months. None of the patients who achieved overall success relapsed. Launch Date 1992

C_max

Value	Dose	Analyte	Population
658.1 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg 1 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ITRACONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
116.8 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ITRACONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
213 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ITRACONAZOLE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT
162 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ITRACONAZOLE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
332 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	HYDROXYITRACONAZOLE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT
974.2 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg 1 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	HYDROXYITRACONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
221.7 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	HYDROXYITRACONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
264 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	HYDROXYITRACONAZOLE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
9046.81 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg 1 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ITRACONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
905.09 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ITRACONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
3.34 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ITRACONAZOLE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT
2.27 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ITRACONAZOLE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
7.05 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	HYDROXYITRACONAZOLE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT
19054.95 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg 1 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	HYDROXYITRACONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
2538.33 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	HYDROXYITRACONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
4.58 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	HYDROXYITRACONAZOLE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
36.84 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg 1 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ITRACONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
36.84 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ITRACONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
20.06 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg 1 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	HYDROXYITRACONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
20.06 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	HYDROXYITRACONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED

F_unbound

Value	Dose	Analyte	Population
0.2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg 1 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ITRACONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
0.2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ITRACONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
0.2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ITRACONAZOLE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT
0.2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ITRACONAZOLE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	HYDROXYITRACONAZOLE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT
0.5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg 1 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	HYDROXYITRACONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
0.5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	HYDROXYITRACONAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
0.5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	HYDROXYITRACONAZOLE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
2.5 mg/kg single, intravenous Dose: 2.5 mg/kg Route: intravenous Route: single Dose: 2.5 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/17517842/	unhealthy, 0.5 - 16 years n = 33 Health Status: unhealthy Condition: risk for fungal infection Age Group: 0.5 - 16 years Sex: M+F Population Size: 33 Sources: https://pubmed.ncbi.nlm.nih.gov/17517842/	Sources: https://pubmed.ncbi.nlm.nih.gov/17517842/
100 mg 2 times / day steady, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: steady Dose: 100 mg, 2 times / day Co-administed with:: hydroxypropyl-beta-cyclodextrin(0.1 g/kg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020657s027lbl.pdf	unhealthy, adult n = 350 Health Status: unhealthy Condition: HIV and oropharyngeal or esophageal candidiasis Age Group: adult Sex: unknown Population Size: 350 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020657s027lbl.pdf	Other AEs: Depression... Other AEs: Depression (2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020657s027lbl.pdf
100 mg 2 times / day steady, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: steady Dose: 100 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020657s027lbl.pdf	unhealthy, adult n = 350 Health Status: unhealthy Condition: HIV and oropharyngeal or esophageal candidiasis Age Group: adult Sex: unknown Population Size: 350 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020657s027lbl.pdf	Other AEs: Nausea, Diarrhea... Other AEs: Nausea (11%) Diarrhea (11%) Vomiting (7%) Abdominal pain (6%) Constipation (2%) Fever (7%) Chest pain (3%) Pain (2%) Fatigue (2%) Coughing (4%) Dyspnea (2%) Pneumonia (2%) Sinusitis (2%) Sputum increased (2%) Rash (4%) Sweating increased (3%) Skin and subcutaneous tissue disorders (2%) Headache (4%) Dizziness (2%) Pneumocystis carinii infection (2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020657s027lbl.pdf
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11249550/	unhealthy, adult Health Status: unhealthy Condition: tinea Age Group: adult Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/11249550/	Sources: https://pubmed.ncbi.nlm.nih.gov/11249550/

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587	inhibitor 1767

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OATP2B1 123 P-gp 1461 CYP2C19 1478 BCRP 699 BSEP 402 MRP1 106 MRP2 383 MRP3 157 MRP4 204 MRP5 22	OCT1 327 UGT1A4 347 OATP1B1 406 OATP1B3 350 OATP2B1 104

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
MRP1 172	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/27001813/	no
MRP2 475	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/27001813/	no
MRP3 207	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/27001813/	no
MRP4 238	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/27001813/	no
MRP5 48	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/27001813/	no
CYP3A4 1925	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/15242978/	strong [IC50 0.0004 uM]	N-desalkyl-itraconazole 2
CYP3A4 1925	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/15242978/	strong [IC50 0.007 uM]	ketoitraconazole 2
CYP3A4 1925	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/27889832/\| https://pubmed.ncbi.nlm.nih.gov/15242978/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	strong [IC50 0.0326 uM]		yes (co-administration study) Comment: [PMID:15242978]: unbound Ki = 1.3 nM; unbound IC50 = 6.1 nM Sources: https://pubmed.ncbi.nlm.nih.gov/27889832/\| https://pubmed.ncbi.nlm.nih.gov/15242978/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf
BCRP 773	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/27001813/	strong [IC50 2 uM]
BSEP 403	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/27001813/	strong [IC50 2 uM]
P-gp 1650	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/11751127/ \| https://pubmed.ncbi.nlm.nih.gov/15969931/\| https://pubmed.ncbi.nlm.nih.gov/19025521/ \| https://pubmed.ncbi.nlm.nih.gov/17304149/ \| https://pubmed.ncbi.nlm.nih.gov/27001813/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	strong [IC50 2 uM]		weak (co-administration study) Comment: Itraconazole increased the mean area under the plasma concentration-time curve [AUC (0-9)] of morphine by 29% (P=0.002), its AUC (0-48) by 22% (P=0.013) and its peak plasma concentration by 28% Sources: https://pubmed.ncbi.nlm.nih.gov/11751127/ \| https://pubmed.ncbi.nlm.nih.gov/15969931/\| https://pubmed.ncbi.nlm.nih.gov/19025521/ \| https://pubmed.ncbi.nlm.nih.gov/17304149/ \| https://pubmed.ncbi.nlm.nih.gov/27001813/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf
CYP3A4 1925	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/15242978/	strong [Ki 0.0144 uM]	hydroxyitraconazole 2
CYP2C19 1553	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/16141567/	yes [IC50 >10 uM]
CYP2C9 1819	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/16141567/	yes [IC50 >10 uM]
OATP2B1 126	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/	yes

Drug as victim

Target	Modality	Activity	Metabolite
OATP1B1 406	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/25106415/	no
OATP1B1 406	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/25106415/	no	hydroxyitraconazole 2
OATP1B3 350	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/25106415/	no
OATP1B3 350	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/25106415/	no	hydroxyitraconazole 2
OATP2B1 104	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/25106415/	no
OATP2B1 104	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/25106415/	no	hydroxyitraconazole 2
OCT1 327	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/25106415/	no
OCT1 327	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/25106415/	no	hydroxyitraconazole 2
UGT1A4 347	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/20304965/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:6076	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6076
MolPort	MolPort-003-848-295	https://www.molport.com/shop/molecule-link/MolPort-003-848-295
Selleck Chemicals	Itraconazole(Sporanox)	http://www.selleckchem.com/products/Itraconazole(Sporanox).html
eMolecules	29541763	https://www.emolecules.com/cgi-bin/more?vid=29541763
eMolecules	36753603	https://www.emolecules.com/cgi-bin/more?vid=36753603
eMolecules	902000	https://www.emolecules.com/cgi-bin/more?vid=902000

PubMed

Title	Date	PubMed
In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.	1998 Dec	10052897
In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp.	1999 Aug	10473237
Severe cholestasis related to intraconazole for the treatment of onychomycosis.	1999 Dec	10606333
[Itraconazole-induced hypokalemia in a patient with pulmonary aspergilloma].	1999 Jan	10087874
In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients.	1999 Nov	10552989
Novel antifungals based on 4-substituted imidazole: solid-phase synthesis of substituted aryl sulfonamides towards optimization of in vitro activity.	2000 Dec 18	11133080
In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B.	2000 Feb	10639380
Synergy between 6-amino-2-n-pentylthiobenzothiazole and ergosterol biosynthesis-inhibiting antimycotics against Candida albicans in vitro.	2000 Jul	10854813
Activity of voriconazole against Candida albicans and Candida krusei isolated since 1984.	2000 Nov	11091037
Clinical activity of the new triazole drug voriconazole (UK 109, 496) against disseminated hepatosplenic aspergillosis in a patient with relapsed leukemia.	2001	11345409
Muscular-skeletal cryptococcosis in a patient with idiopathic CD4+ lymphopenia.	2001	11307596
Electrophoretic karyotyping and antifungal susceptibility patterns of Candida parapsilosis clinical isolates causing deep and superficial fungal infections.	2001	11307593
Pharmacology of itraconazole.	2001	11219548
Current management of fungal infections.	2001	11219547
DNA fingerprinting of serial Candida albicans isolates obtained during itraconazole prophylaxis in patients with AIDS.	2001 Apr	11346270
Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.	2001 Apr	11259329
Hereditary palmoplantar keratoderma (four cases in three generations).	2001 Feb	11328395
Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species.	2001 Feb	11270414
[New developments in medical mycology].	2001 Feb	11244898
Cutaneous alternariosis in a cardiac transplant recipient.	2001 Feb	11233722
A case report of a dactylaria fungal infection in a lung transplant patient.	2001 Feb	11171754
Lymphadenitis caused by Scedosporium apiospermum in an immunocompetent patient.	2001 Feb 1	11170973
Characterization of glassy itraconazole: a comparative study of its molecular mobility below T(g) with that of structural analogues using MTDSC.	2001 Feb 1	11165104
Itraconazole: an effective oral antifungal for onychomycosis.	2001 Jan	11277944
Successful treatment of Paecilomyces lilacinus endophthalmitis after foreign body trauma to the cornea.	2001 Jan	11188992
The combination of oral amphotericin B with azoles prevents the emergence of resistant Candida species in neutropenic patients.	2001 Jan	11167799
Cure of experimental Chagas' disease by the bis-triazole DO870 incorporated into 'stealth' polyethyleneglycol-polylactide nanospheres.	2001 Jan	11152439
Oropharyngeal candidiasis in patients with human immunodeficiency virus: correlation of clinical outcome with in vitro resistance, serum azole levels, and immunosuppression.	2001 Jun 1	11340526
Long-term follow-up study of onychomycosis: cure rate and dropout rate with oral antifungal treatments.	2001 Mar	11349463
Trends in frequency and susceptibilities of Candida glabrata bloodstream isolates at a university hospital.	2001 Mar	11337190
Oral antifungals as prophylaxis in haematological malignancy.	2001 Mar	11333134
Malassezia pachydermatis fungaemia in a neonatal intensive care unit.	2001 Mar	11332175
Allergic bronchopulmonary disease caused by Bipolaris hawaiiensis presenting as a necrotizing pneumonia: case report and review of literature.	2001 Mar	11269801
Clinical inquiries. What is the best oral antifungal medication for tinea capitis?	2001 Mar	11252205
Blastomycosis of the petrous apex.	2001 Mar	11241008
In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.	2001 Mar	11230410
Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.	2001 Mar	11181372
Quantitation of itraconazole in rat heparinized plasma by liquid chromatography-mass spectrometry.	2001 Mar 5	11254202
Lymphomatoid granulomatosis after childhood acute lymphoblastic leukemia: report of effective therapy.	2001 May	11331732
Effect of inoculum form on in vitro antifungal susceptibilities of Aspergillus spp.	2001 May	11328793
Itraconazole for treatment of sporotrichosis in a dog residing on a Christmas tree farm.	2001 May 1	11345307

Patents

Sample Use Guides

In Vivo Use Guide

Blastomycosis and Histoplasmosis: The recommended dose is 200 mg once daily (2 capsules). If there is no obvious improvement, or there is evidence of progressive fungal disease, the dose should be increased in 100-mg increments to a maximum of 400 mg daily. Doses above 200 mg/day should be given in two divided doses. Aspergillosis: A daily dose of 200 to 400 mg is recommended. Treatment in Life-Threatening Situations: In life-threatening situations, a loading dose should be used. Although clinical studies did not provide for a loading dose, it is recommended, based on pharmacokinetic data, that a loading dose of 200 mg (2 capsules) three times daily (600 mg/day) be given for the first 3 days of treatment. Onychomycosis: Toenails with or without fingernail involvement: The recommended dose is 200 mg (2 capsules) once daily for 12 consecutive weeks. Onychomycosis: Fingernails only: The recommended dosing regimen is 2 treatment pulses, each consisting of 200 mg (2 capsules) b.i.d. (400 mg/day) for 1 week.

Route of Administration: Oral

In Vitro Use Guide

The growth inhibition effects of different concentrations of itraconazole ITC (2, 6, 15 µmol/L) was detected by CCK8 assay in KG1α and primary adult acute leukemia cells. Different concentrations of ITC for 7, 14 and 21 days were applied for observing the effect on colony formation. After 48 h treatments with 6 µmol/L ITC the morphological changes of cells were observed by Wright staining.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:06:52 GMT 2023` Edited by `admin` on `Fri Dec 15 16:06:52 GMT 2023`
Record UNII	304NUG5GF4
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ITRACONAZOLE

Official Name

English

SUBA-ITRACONAZOLE COMPONENT ITRACONAZOLE

Common Name

English

ITRACONAZOLE [USAN]

Common Name

English

ITRACONAZOLE [INCI]

Common Name

English

SPORANOX

Brand Name

English

ORUNGAL

Brand Name

English

ITRALEK

Brand Name

English

ITRACONAZOLE (EMA EPAR: VETERINARY)

Common Name

English

ITRACONAZOLE [ORANGE BOOK]

Common Name

English

FUNGITRAXX

Brand Name

English

CANDISTAT

Brand Name

English

3H-1,2,4-TRIAZOL-3-ONE, 4-(4-(4-(4-((2-(2,4-DICHLOROPHENYL)-2-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL)-1-PIPERAZINYL)PHENYL)-2,4-DIHYDRO-2-(1-METHYLPROPYL)-

Systematic Name

English

SPORAMELT

Brand Name

English

ITRACONAZOLE [MART.]

Common Name

English

SEMPERA

Brand Name

English

ITRIZOLE

Brand Name

English

SPORONOX

Brand Name

English

SPHERAZOLE CR

Brand Name

English

NSC-759239

Code

English

ITRACONAZOLE [EP IMPURITY]

Common Name

English

ITRACONAZOLE [EP MONOGRAPH]

Common Name

English

ITRACONAZOLE [VANDF]

Common Name

English

CLADOSAL 100

Brand Name

English

TRACONAL

Brand Name

English

ITRACONAZOLE [USP-RS]

Common Name

English

ITRACONAZOLE [JAN]

Common Name

English

R 51,211

Code

English

R-51211

Code

English

(±)-1-SEC-BUTYL-4-(P-(4-(P-(((2R*,4S*)-2-(2,4-DICHLOROPHENYL)-2-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL)-1-PIPERAZINYL)PHENYL)-.DELTA.(SUP 2)-1,2,4-TRIAZOLIN-5-ONE

Common Name

English

ITRACONAZOLE COMPONENT OF SUBA-ITRACONAZOLE

Common Name

English

SPHERAZOLE IR

Brand Name

English

itraconazole [INN]

Common Name

English

TRIASPORIN

Brand Name

English

ITRACONAZOLE [USP MONOGRAPH]

Common Name

English

Itraconazole [WHO-DD]

Common Name

English

CANDITRAL

Brand Name

English

ITRACONAZOLE [GREEN BOOK]

Common Name

English

ITRAC

Brand Name

English

ITRACONAZOLE [MI]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QJ02AC02